Big Data in Oncology: Impact, Challenges, and Risk Assessment


Book Description

We are in the era of large-scale science. In oncology there is a huge number of data sets grouping information on cancer genomes, transcriptomes, clinical data, and more. The challenge of big data in cancer is to integrate all this diversity of data collected into a unique platform that can be analyzed, leading to the generation of readable files. The possibility of harnessing information from all the accumulated data leads to an improvement in cancer patient treatment and outcome. Solving the big data problem in oncology has multiple facets. Big data in Oncology: Impact, Challenges, and Risk Assessment brings together insights from emerging sophisticated information and communication technologies such as artificial intelligence, data science, and big data analytics for cancer management. This book focuses on targeted disease treatment using big data analytics. It provides information about targeted treatment in oncology, challenges and application of big data in cancer therapy. Recent developments in the fields of artificial intelligence, machine learning, medical imaging, personalized medicine, computing and data analytics for improved patient care. Description of the application of big data with AI to discover new targeting points for cancer treatment. Summary of several risk assessments in the field of oncology using big data. Focus on prediction of doses in oncology using big data The most targeted or relevant audience is academics, research scholars, health care professionals, hospital management, pharmaceutical chemists, the biomedical industry, software engineers and IT professionals.




Opportunities and Challenges for Using Digital Health Applications in Oncology


Book Description

Digital health encompasses a broad array of tools and strategies with the goals of advancing research, increasing health care access and quality, and making care more personalized. It encompasses health content, digital health interventions, and digital applications, such as communication tools connecting patients and clinicians (e.g., secure email in the patient portal, text, chat, video visit), remote monitoring tools, clinical decision support tools, and systems for exchanging health information. Patient-facing tools, tools for clinicians, and systems to facilitate research and care improvement are all part of this diverse landscape, and each raises unique opportunities and potential challenges. To examine key policy issues for the effective and safe development, implementation, and use of digital health technologies in oncology research and care, the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine held a virtual workshop in collaboration with the Forum on Cyber Resilience. The workshop, Opportunities and Challenges for Using Digital Health Applications in Oncology, held on July 13-14, 2020, convened a broad group of experts, including clinicians and researchers; patient advocates; and representatives of federal agencies, health professional societies, health care organizations, insurers, and the pharmaceutical and health technology industries. Many workshop speakers found the opportunities presented by digital health tools to be particularly compelling for oncology; however, capitalizing on these opportunities necessitates careful attention to the design, implementation, and use of digital health technologies. This publication summarizes the presentations and discussions from the workshop.




Cancer Informatics


Book Description

Cancer Informatics chronicles the development of the National Cancer Institute's new Cancer Informatics Infrastructure (CII) - an information management system infrastructure designed to faciliate clinical trials, provide for reliable, secure information exchange, and improve patient care. The book details the challenges involved in creating and managing such a knowledge base, including technologies, standards, and current, state-of-the-art applications. The ultimate goal of CII is to function as an enabler of clinical trials, expediting the clinical trials lifecycle, faciliating faster and safer drug development and more appropriate treatment choices for cancer patients. Contributors address the role the CII must play in converting the growing knowledge of genes, proteins, and pathways into appropriate preventative, diagnostic, and therapeutic measures. Presented in four sections, the first provides an overview of the processes involved in moving the infrastructure for cancer from theory into practice. Sections two through four offer the latest work done in the areas of technology, cancer-specific and national standards, and applications to faciliate clinical trials.




Improving Cancer Diagnosis and Care


Book Description

Rapid advances in cancer research, the development of new and more sophisticated approaches to diagnostic testing, and the growth in targeted cancer therapies are transforming the landscape of cancer diagnosis and care. These innovations have contributed to improved outcomes for patients with cancer, but they have also increased the complexity involved in diagnosis and subsequent care decisions. To examine opportunities to improve cancer diagnosis and care, the National Academies of Sciences, Engineering, and Medicine developed a two-workshop series. The first workshop, held on February 12â€"13, 2018, in Washington, DC, focused on potential strategies to ensure that patients have access to appropriate expertise and technologies in oncologic pathology and imaging to inform their cancer diagnosis and treatment planning, as well as assessment of treatment response and surveillance. This publication chronicles the presentations and discussions at the workshop.




The Digital Revolution in Health


Book Description

What sort of health system do we want to implement in the face of the imminent arrival of artificial intelligence and robotics in medical practices? The Covid-19 health crisis has demonstrated the importance of digital technologies in the care of patients and their families, as imperative attention was called to ethics and relational practice. This book analyzes numerous sources of feedback to reveal the multiple facets of this so-called Medicine 4.0. It reveals the extent to which digital medicine requires new forms of organization and new approaches to co-conception, in a logic that is resolutely collaborative with patients. The book concludes with legal and ethical points of view in order to challenge the reader on their duty to truly be an "actor" of their health care.




Economic Evaluation of Cancer Drugs


Book Description

Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity’s Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.




Personalized Medicine in Oncology


Book Description

Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first “site-agnostic” drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic “signatures” that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.




Oncology Informatics


Book Description

Oncology Informatics: Using Health Information Technology to Improve Processes and Outcomes in Cancer Care encapsulates National Cancer Institute-collected evidence into a format that is optimally useful for hospital planners, physicians, researcher, and informaticians alike as they collectively strive to accelerate progress against cancer using informatics tools. This book is a formational guide for turning clinical systems into engines of discovery as well as a translational guide for moving evidence into practice. It meets recommendations from the National Academies of Science to "reorient the research portfolio" toward providing greater "cognitive support for physicians, patients, and their caregivers" to "improve patient outcomes." Data from systems studies have suggested that oncology and primary care systems are prone to errors of omission, which can lead to fatal consequences downstream. By infusing the best science across disciplines, this book creates new environments of "Smart and Connected Health." Oncology Informatics is also a policy guide in an era of extensive reform in healthcare settings, including new incentives for healthcare providers to demonstrate "meaningful use" of these technologies to improve system safety, engage patients, ensure continuity of care, enable population health, and protect privacy. Oncology Informatics acknowledges this extraordinary turn of events and offers practical guidance for meeting meaningful use requirements in the service of improved cancer care. Anyone who wishes to take full advantage of the health information revolution in oncology to accelerate successes against cancer will find the information in this book valuable. Presents a pragmatic perspective for practitioners and allied health care professionals on how to implement Health I.T. solutions in a way that will minimize disruption while optimizing practice goals Proposes evidence-based guidelines for designers on how to create system interfaces that are easy to use, efficacious, and timesaving Offers insight for researchers into the ways in which informatics tools in oncology can be utilized to shorten the distance between discovery and practice




The Creative Destruction of Medicine


Book Description

A professor of medicine reveals how technology like wireless internet, individual data, and personal genomics can be used to save lives.